CLA 1 Fat Burner

Product Rating: 
0
SKU: 4086
$39.99

 

Applications for Health Improvement

  • Supports healthy body composition
  • Helps decrease catabolic effect of training on muscle protein
  • Affects the production of cytokines and arachidonic acis derived eicosanoids
  • Supports reduction in body fat mass (BFM)

 

120 Softgels

780 mg/capsule

 

Conjugated linoleic acid (CLA) is a fatty acid found in small amounts in the human diet. While CLA in the diet is found primarily in dairy products and beef fat, CLA 1 Fat Burner is derived from pure, non-GMO safflower oil.

This is a patented form of conjugated linoleic acid (CLA). The yield of CLA is at least 78%, providing 1.56 g of pure CLA per serving. Research using higher doses of CLA (via supplementation) suggests that it reduces body fat in a dose-related manner. A 2007 meta-analysis of randomized, double-blind, placebo controlled (RDBPC) human trials revealed that a mean dose of 3.2 g CLA per day produced modest fat loss in human subjects [1]. Four capsules of CLA 1 Fat Burner provides 3.12 g of CLA in a 50:50 ratio of cis-9,trans-11 (c9,t11) and trans-10,cis-12 (t10,c12) isomers, the composition commonly used in clinical studies. Though c9,t11 is the principal CLA isomer found in food, t10,c12 appears to specifically affect fat cells by inhibiting lipoprotein lipase and stearoyl-CoA desaturase, resulting in reduced uptake of lipids into adipocytes [2].

A three-month RDBPC study of 60 overweight or obese volunteers was conducted utilizing various doses of CLA. A significantly higher reduction in body fat mass (BFM) was seen in all CLA groups compared to placebo. However, no further reduction in BFM occurred with doses >3.4 g/day [3]. A six-month clinical trial suggested that fat loss from CLA supplementation occurred primarily in the abdominal area and legs of females and in the abdomen of males without specific diet or exercise efforts. No adverse effects on blood parameters or insulin sensitivity were observed [4]. A 12-month extension study suggested that long-term CLA supplementation decreased BFM, was well tolerated, and helped maintain reductions in body fat and weight over time [5].

CLA supplementation was found to decrease body fat percentage even in normal weight subjects. Without changing diet, calorie intake, or lifestyle, the group consuming 2.4 g CLA in an RDBPC study experienced a decrease in body fat from 21.3 to 17% (representative of a 15-20% reduction in fat but no change in weight) while the placebo group experienced an increase in body fat [6,7]. A study of 44 healthy young women suggested that supplementing with 3.6 g of CLA alone or with exercise helped maintain healthy glucose metabolism [8].

 

References

  1. Whigham LD, Watras AC, Schoeller DA. Efficacy of conjugated linoleic acid for reducing fat mass: a meta-analysis in humans. Am J Clin Nutr. 2007 May;85(5):1203-11. [PMID: 17490954]
  2. Pariza MW, Park Y, Cook ME. The biologically active isomers of conjugated linoleic acid. Prog Lipid Res. 2001 Jul;40(4):283-98. [PMID: 11412893]
  3. Blankson H, Stakkestad JA, Fagertun H, et al. Conjugated linoleic acid reduces body fat mass in overweight and obese humans. J Nutr. 2000 Dec;130(12):2943-8. [PMID: 11110851]
  4. Clarinol. http://www.clarinol.com/HealthBenefits/ResearchResults/. Accessed August 16, 2012.
  5. Gaullier JM, Halse J, Høye K, et al. Supplementation with conjugated linoleic acid for 24 months is well tolerated by and reduces body fat mass in healthy, overweight humans. J Nutr. 2005 Apr;135(4):778-84. [PMID: 15795434]
  6. Pizzorna, LU, Pizzorno, JE, Murray MT. Natural Medicine Instructions for Patients. Churchill Livingstone; 2002
  7. Thom E, Wadstein J, Gudmundsen O. Conjugated linoleic acid reduces body fat in healthy exercising humans. J Int Med Res. 2001 Sep-Oct;29(5):392-6. [PMID: 11725826]
  8. Colakoglu S, Colakoglu M, Taneli F, et al. Cumulative effects of conjugated linoleic acid and exercise on endurance development, body composition, serum leptin and insulin levels. J Sports Med Phys Fitness. 2006 Dec;46(4):570-7. [PMID: 17119522]